Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open‐label, single‐arm, noncomparative trial - Chen - 2018 -
1175-Colorectal metastatic capecitabine and beVACizumab | eviQ
Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data | Future Oncology
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study - ScienceDirect
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label,
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised ...
Colorectal Cancer – Treatments | Gastrointestinal Cancer
Frontiers | FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
Trifluridine/Tipiracil Combination Misses Mark in Metastatic Colon Cancer | MedPage Today
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Erbitux®/Avastin®/Camptosar® Appears Effective in Colorectal Cancer Patients - CancerConnect
Use of Bevacizumab in the Maintenance Setting for Patients with Metastatic Colorectal Cancer (mCRC) | Research To Practice
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer | NEJM
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook - Cancer Treatment Reviews
Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal carcinoma | Semantic Scholar
Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer | BMC Cancer
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Avastin® (bevacizumab) Dosing | MCRC Treatment
PPT - Background PowerPoint Presentation, free download - ID:2215849
Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram
Maintenance Treatment With Capecitabine and Bevacizumab Is Effective in Metastatic Colorectal Cancer - The ASCO Post
Avastin with Xeloda as a first-line treatment for metastatic breast cancer bc_en | PDF
